ArticleCancer pathogenesis and therapy2024

Efficacy and toxicity of anlotinib plus camrelizumab versus anlotinib plus S-1 as second-line therapy for advanced esophageal squamous cell carcinoma: A real-world retrospective study.

Wei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.